Acquisition History Infusionz was acquired by Bloomios Inc in late 2022 for 23.5 million, signaling integration into a larger cannabinoid products ecosystem. This presents a potential cross-sell opportunity for portfolio expansion to Bloomios’ existing customers and distribution channels.

Private Label Readiness As a completed manufacturer of finished CBD, CBG, and CBN products with white-label and private-label capabilities, Infusionz aligns well with distributors and retailers seeking turn-key CBD product lines to accelerate shelf presence.

Smaller Scale Advantage With 11-50 employees and annual revenue in the low millions, Infusionz offers a nimble, high-quality manufacturing partner ideal for boutique brands, private-label launches, or regional rollouts seeking reliable led by hands-on management.

Tech-Driven Ops Utilizes a modern digital stack (WooCommerce, Klaviyo, WordPress, Cloudflare) suggesting strong e-commerce enablement and direct-to-consumer channels, which can be leveraged for co-marketing, CRM storytelling, and data-driven sales campaigns.

Expansion Synergy Recent acquisition activity combined with an established reputation in hemp finished products indicates opportunity to propose scaled production capacity, new product formats, or contract manufacturing to expand into additional cannabinoids or pet/nutrition segments.